Oncology

Latest News

Patients in the cemiplimab group had superior disease-free survival vs placebo. | Image credit: Medical Works - stock.adobe.com
Cemiplimab Improves Disease-Free Survival in High-Risk, Advanced CSCC

June 13th 2025

Cemiplimab improved disease-free survival in patients with high-risk cutaneous squamous cell carcinoma (CSCC) and performed well in patients with advanced CSCC in the real-world setting.

The approval covers use of pembrolizumab as a single agent in the neoadjuvant setting, followed by adjuvant treatment with pembrolizumab in combination with radiotherapy with or without cisplatin after surgery, and then continued as a single agent. | Image credit: wladimir1804-stock.adobe.com
FDA Approves Perioperative Pembrolizumab in Resectable HNSCC

June 13th 2025

FDA approval-Olivier Le Moal-stock.adobe.com.jpeg
Mitomycin Intravesical Solution Gains FDA Approval for Recurrent Low-Grade NMIBC

June 12th 2025

AJMC
Utilization and Costs Among Oncologists Participating in a Private Insurance Shared Savings Model

June 11th 2025

The new report suggests the C5a-C5aRq axis might be a useful target in combination with existing therapies for cutaneous squamous cell carcinoma. | Image credit: vladimircaribb - stock.adobe.com
C5aR1 Flagged as Biomarker in Cutaneous Squamous Cell Carcinoma

June 7th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Site Logo
November 7th 2016

Meta-Analysis Confirms Clinical Advantage of BRAF/MEK and PD-1 Inhibitors in Melanoma

Surabhi Dangi-Garimella, PhD
Based on a retrospective meta-analysis of clinical trial data, authors of a recent paper in JAMA Oncology concluded that BRAF/MEK and programmed death receptor-1 (PD-1) inhibitors were the most effective treatments that were relatively safe in melanoma.
Site Logo
November 7th 2016

Value of Second Opinion in Prostate Cancer Uncertain, Says Hopkins Study

Surabhi Dangi-Garimella, PhD
A new study by researchers at the Johns Hopkins University has found that second opinions did not change treatment choice among men diagnosed with low-risk prostate cancer.
Site Logo
November 4th 2016

A Diagnostic Tool for Cachexia in Cancer Patients Could Save Lives

Surabhi Dangi-Garimella, PhD
Researchers from Canada’s McGill University have developed a potential tool that can detect early signs of cachexia in cancer patients, which could impact survival.
Site Logo
November 4th 2016

Genetic Counseling Prerequisite Reduced Appropriate Testing, Study Finds

Surabhi Dangi-Garimella, PhD
A new study in the Journal of Oncology Practice has found that the health plan requirement of counseling by certified geneticists could have led to patient access issues in oncology.
Site Logo
November 3rd 2016

ASCO's Collaboration Will Expand the Reach of COME HOME for Oncology Patients

Surabhi Dangi-Garimella, PhD
The American Society of Clinical Oncology (ASCO) has announced that it is collaborating with Innovative Oncology Business Solutions, Inc, on ASCO COME HOME.
Segment 8 - Covering the Gaps in Cancer Survivor Care
November 3rd 2016

Segment 8 - Covering the Gaps in Cancer Survivor Care

How can care providers ensure cancer survivors continue to receive adequate follow-up care post treatment?
Segment 7 - Successful Discussions on Advance Care Planning and EOL
November 3rd 2016

Segment 7 - Successful Discussions on Advance Care Planning and EOL

How can discussions on advance care planning and end-of-life care be successfully broached with patients and their family members?
Segment 6 - Reimbursing Value-Based Oncology Care
November 3rd 2016

Segment 6 - Reimbursing Value-Based Oncology Care

Panelists discussed how patient-centered care can be valuated in the changing healthcare climate.
Segment 5 - An Ideal Patient Portal
November 3rd 2016

Segment 5 - An Ideal Patient Portal

Is there anything like an ideal patient portal that can cater to a broad range of patients? According to Rebekkah Schear, MIA, what patient portals lack is a holistic approach toward the patient.
Segment 4 - Overcoming Barriers With Data Exchange
November 3rd 2016

Segment 4 - Overcoming Barriers With Data Exchange

How can we create more standardized health information platforms that can easily exchange patient information?
Segment 3 - Challenges With Oncology Care Navigation
November 3rd 2016

Segment 3 - Challenges With Oncology Care Navigation

Cancer is a complex disease to treat an patients can be overwhelmed by the number of care providers that they have to consult with. In this scenario, care navigators can provide significant support to patients and their family members.
Segment 2 - Documenting the Treatment Plan
November 3rd 2016

Segment 2 - Documenting the Treatment Plan

Panelists discuss the need for documenting a treatment plan early in patient care.
Segment 1 - Patient-Centered Care and Shared Decisions in Oncology
November 3rd 2016

Segment 1 - Patient-Centered Care and Shared Decisions in Oncology

Joseph Alvarnas, MD, editor-in-chief of Evidence-Based-OncologyTM spoke with Rebekkah Schear, MIA, and Michael Kolodziej, MD, to discuss the progress and challenges in oncology care.
Dr Andrew L. Pecora Outlines Issues Oncologists Have With Value Frameworks
November 2nd 2016

Dr Andrew L. Pecora Outlines Issues Oncologists Have With Value Frameworks

Oncologists are aware of the various value frameworks that have popped up recently, but they are still in the first phase and many oncologists have issues with the frameworks, said Andrew L. Pecora, MD, FACP, CPE, chief innovation officer professor and vice president of cancer services at the John Theurer Cancer Center.
Site Logo
November 1st 2016

Chemo Brain May Have a Solution: Insight

Surabhi Dangi-Garimella, PhD
A new study suggests that a Web-based intervention could improve a cancer survivor’s cognitive function post treatment.
Site Logo
November 1st 2016

CVS Reverses Decision on Physician Dispensing of Oncology Drugs

Surabhi Dangi-Garimella, PhD
CVS Health has reversed its decision on physician dispensing of specialty drugs, originally meant to be implemented by January 1, 2017.
Site Logo
October 31st 2016

Phase I Study Indicates Pembrolizumab an Option in Heavily Pretreated Hodgkin Lymphoma

AJMC Staff
A small, early-stage study in patients with Hodgkin lymphoma who had failed multiple treatments or relapsed after stem cell transplant indicates that pembrolizumab could be a favorable treatment option in these patients.
Site Logo
October 31st 2016

Researchers Aren't Taking Advantage of Clinical Trial Data-Sharing Project

Surabhi Dangi-Garimella, PhD
A perspective piece, published by researchers from Rutgers University, laments the lack of interest shown by researchers in a clinical trial data-sharing project launched in January 2014.
Site Logo
October 28th 2016

Study Results Could Help Strengthen Response to Checkpoint Inhibitors

Surabhi Dangi-Garimella, PhD
An animal study conducted at the Perelman School of Medicine, University of Pennsylvania, has identified a mechanism to strengthen the immune response of T cells in cancer patients who are treated with checkpoint inhibitors.
This Week in Managed Care: October 28, 2016
October 28th 2016

This Week in Managed Care: October 28, 2016

This week, the top stories in managed care included an announcement that premiums on Obamacare plans are set to increase by 25% on average, a discussion of Medicare Advantage growth at America's Health Insurance Plans' National Conference on Medicare, and recommendations for success with the Oncology Care Model.
Dr Scott Gottlieb: PCOC Is a Good Place to Meet Thought Leaders in Oncology
October 28th 2016

Dr Scott Gottlieb: PCOC Is a Good Place to Meet Thought Leaders in Oncology

Patient-Centered Oncology Care offers attendees the opportunity to meet and interact with high-level people from various segments of the healthcare industry, explained Scott Gottlieb, MD, resident fellow at the American Enterprise Institute.
Site Logo
October 27th 2016

Age Is Not a Risk Factor for Post-Mastectomy Reconstructive Surgery

Surabhi Dangi-Garimella, PhD
Long-term follow-up of women who underwent mastectomy and breast reconstruction subsequent to a breast cancer diagnosis found that the success of the procedure and associated complications were not influenced by the woman’s age.
Site Logo
October 26th 2016

Will a Payer—Provider Collaboration Guarantee OCM Success?

Surabhi Dangi-Garimella, PhD
At the Payer Exchange Summit V, sponsored by the Community Oncology Alliance, oncologists and payers came together to discuss the role of collaboration and data sharing for the successful implementation of the Oncology Care Model.
Site Logo
October 26th 2016

Employers Express Their Concerns With Cancer Care at the COA Summit

Surabhi Dangi-Garimella, PhD
At the Payer Exchange Summit V, sponsored by the Community Oncology Alliance (COA), 2 employer groups and a provider participated on a panel to provide practical insight into the extraordinary challenges and decisions faced by employers and employees with a cancer diagnosis.
Dr Karen van Caulil on Value-Based Oncology Care Models for Large Employers
October 26th 2016

Dr Karen van Caulil on Value-Based Oncology Care Models for Large Employers

When transitioning towards value-based oncology, large employers should look to value-based models that have worked for other conditions, said Karen van Caulil, PhD, president and CEO of the Florida Health Care Coalition. These successful payment models include patient-centered medical homes, bundled payments, and accountable care organizations.
Barry Russo Discusses Challenges of Juggling OCM and MIPS
October 26th 2016

Barry Russo Discusses Challenges of Juggling OCM and MIPS

Many oncology practices are still trying to understand the new Oncology Care Model (OCM) structure and focus on data reporting as they simultaneously prepare to adapt to the Merit-based Incentive Payment System (MIPS), said Barry Russo, CEO of The Center for Cancer & Blood Disorders.
Site Logo
October 25th 2016

Pembrolizumab Is FDA-Approved as First-Line for PD-L1—Positive NSCLC

AJMC Staff
Patients newly diagnosed with non—small cell lung cancer (NSCLC) that expresses the programmed death ligand-1 (PD-L1) protein now have a new treatment option: pembrolizumab (Keytruda).
Site Logo
October 25th 2016

Strategies for OCM Implementation at the COA Payer Summit

Surabhi Dangi-Garimella, PhD
What are some of the challenges that clinical practices will face as they implement the Medicare Oncology Care Model (OCM)? What are some of the strategies that have worked for practices using similar payment models? These were some of the questions discussed at the Payer Exchange Summit V.
Site Logo
October 25th 2016

How Can Practices Seek Success With Oncology Payment Reform?

Surabhi Dangi-Garimella, PhD
At the Payer Exchange Summit V, sponsored by the Community Oncology Alliance, held October 24-25, 2016, in Tyson’s Corner, Virginia, Bruce Gould, MD, presented an overview of how cancer care has improved over the years, what the challenges are, and how practices can adapt to payment reform.
Dr Marianne Fazen on Why Cancer Is a Major Concern for Employers
October 25th 2016

Dr Marianne Fazen on Why Cancer Is a Major Concern for Employers

Employers face tough decisions about rising costs, high-quality care, coordination of benefits, and workplace accommodations when employees are diagnosed with cancer, but they will always want to support those employees as best they can, according to Marianne Fazen, PhD, president and CEO of the Texas Business Group on Health.
<1
...
899091929394959697
...
186>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo